• Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
Stock

Pfizer close to acquiring Metsera for $7.3B, targeting breakthrough obesity drug

by September 22, 2025
by September 22, 2025

Pfizer is making a bold move in the pharmaceutical world by closing in on a $7.3 billion deal to acquire Metsera, a biotech firm focused on next-generation anti-obesity drugs, news platform Financial Times reported on Monday.

This acquisition underlines Pfizer’s fresh push into the booming weight-loss drug market, an area showing rapid growth as obesity rates climb worldwide.

After facing challenges with its own weight loss drug programs, Pfizer sees this as a strategic way to strengthen its portfolio and join the race against established leaders in obesity treatments.

Pfizer eyes Metsera obesity breakthrough

The deal offers Metsera shareholders $47.50 per share in cash, with an additional $22.50 per share payable if certain performance targets are hit.

This premium of about 42% over Metsera’s recent share price reflects Pfizer’s eagerness to secure the promising biotech.

Metsera, based in New York and founded in 2022, has been developing innovative obesity treatments primarily through GLP-1 receptor agonists.

Its standout drug candidate, MET-097i, is designed to be injected once a month and has shown an average weight loss of 11.3% in mid-stage clinical trials, a major convenience leap compared to the weekly injections offered by Pfizer’s competitors.

Pfizer’s acquisition would be a sharp turnaround after it halted its own oral GLP-1 drug development earlier this year due to safety issues.

The deal, expected to be announced soon pending final talks, gives Pfizer access to Metsera’s pipeline, which includes potential combination therapies, positioning the company well in the obesity treatment space.

This payment structure, blending cash upfront with milestone incentives, aligns costs with drug development success, lowering some risk for Pfizer while aiming for high rewards.

Obesity drug race heats up

Pfizer’s move is a clear sign of how hot the obesity drug market has become, dominated until now by giants like Novo Nordisk and Eli Lilly.

These firms have scored major wins with GLP-1 therapies enabling significant weight loss, but Pfizer sees an opportunity with Metsera’s once-monthly dosing, which could attract patients looking for easier treatment options and improve drug adherence.

This deal highlights the trend of big pharma companies aggressively buying into promising biotech startups to keep pace with innovation rather than relying solely on internal development.

The acquisition also raises the stakes, as the anti-obesity market is forecasted to explode to nearly $100 billion by 2030, driven by demand for more effective, patient-friendly treatments.

While milestone-based payments introduce risk if Metsera’s drugs fall short in trials, Pfizer’s bet signals confidence in this expanding field.

The acquisition is poised to intensify competition and could spark more deals and technological advances, as companies race to capture a share of the lucrative, fast-evolving obesity drug market.

Ultimately, Pfizer’s bold purchase aims to place it among the leaders challenging the current duopoly and addressing a critical global health issue.

The post Pfizer close to acquiring Metsera for $7.3B, targeting breakthrough obesity drug appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Will Rolls-Royce share price hit 1,250p as Goldman Sachs predicts?
next post
Pam Bondi is Wrong: Hate Speech Is Free Speech

Related Posts

OpenAI valuation hits $500 billion as employees sell...

October 2, 2025

Here’s why JPMorgan, Morningstar are bullish on Alibaba...

October 2, 2025

Europe markets open: Stoxx 600 jumps 0.6%, led...

October 2, 2025

Will the Tesco share price hit 500p as...

October 2, 2025

Tesco lifts profit forecast as summer, price cuts,...

October 2, 2025

Chinese carmakers expand hybrid sales in Europe as...

October 2, 2025

Hackers exploit Oracle systems, executives hit with ransom...

October 2, 2025

US digest: TrumpRx launch, job data, and government...

October 1, 2025

Asian markets: Nikkei sinks 1.16%, Sensex muted ahead...

October 1, 2025

Morning brief: Asian factory data splits on US...

October 1, 2025

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

Recent Posts

  • Wiliot and Walmart Partner to Transform Retail with Ambient IoT and AI

    October 2, 2025
  • Manual trades embracing IoT for safer workplaces

    October 2, 2025
  • Soracom and Skylo Roll Out Integrated Satellite IoT

    October 2, 2025
  • Mission Creep: The Fed’s Foray Into State and Local Debt

    October 2, 2025
  • I Was a Victim of Cancel Culture. Don’t Perpetuate It.

    October 2, 2025
  • OpenAI valuation hits $500 billion as employees sell $6.6 billion in shares

    October 2, 2025

Editors’ Picks

  • 1

    Meta executives eligible for 200% salary bonus under new pay structure

    February 21, 2025
  • 2

    Walmart earnings preview: What to expect before Thursday’s opening bell

    February 20, 2025
  • 3

    New FBI leader Kash Patel tapped to run ATF as acting director

    February 23, 2025
  • 4

    Cramer reveals a sub-sector of technology that can withstand Trump tariffs

    March 1, 2025
  • 5

    Anthropic’s newly released Claude 3.7 Sonnet can ‘think’ as long as the user wants before giving an answer

    February 25, 2025
  • 6

    Nvidia’s investment in SoundHound wasn’t all that significant after all

    March 1, 2025
  • 7

    Pop Mart reports 188% profit surge, plans aggressive global expansion

    March 26, 2025

Categories

  • Economy (2,758)
  • Editor's Pick (279)
  • Investing (185)
  • Stock (1,879)
  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Read alsox

LSEG share price crashes despite strong fundamentals:...

August 13, 2025

BBAI stock soars 21% today as AI...

July 1, 2025

EU-US trade deal: 15% tariff, $750B energy...

July 28, 2025